不同类型肝窦阻塞综合征的临床特征、发病机制与诊治

刘贞利; 范作鹏; 勾钰淞; 柳雅立; 张晶

doi:10.3969/j.issn.1001-5256.2019.01.046

不同类型肝窦阻塞综合征的临床特征、发病机制与诊治

DOI: 10.3969/j.issn.1001-5256.2019.01.046

首都医科大学附属北京佑安医院丙型肝炎与中毒性肝病科

基金项目:

艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2018ZX10715005-003-003)；

详细信息

中图分类号: R575
计量
- 文章访问数: 2283
- HTML全文浏览量: 165
- PDF下载量: 383
- 被引次数: 0
出版历程
- 出版日期: 2019-01-20

Clinical features, pathogenesis, and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome

Department of Hepatitis C & Toxic Liver Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

摘要

摘要:
肝窦阻塞综合征(HSOS)是一种肝窦或肝小静脉纤维闭塞性疾病,肝小血管损伤特别是肝窦内皮细胞损伤为其主要特征。接触某些外源性毒性物质是其主要致病原因。根据病因不同,HSOS主要包括以下类型:吡咯生物碱相关肝窦阻塞综合征;造血干细胞移植相关肝窦阻塞综合征;其他病因不明的肝窦阻塞综合征。对HSOS不同分类进行概述,简述了HSOS的临床表现、发病机制、诊断和治疗等方面的研究进展。
- 肝静脉闭塞性疾病 /
- 生物碱类 /
- 造血干细胞移植 /
- 综述
Abstract:
Hepatic sinusoidal obstruction syndrome (HSOS) is a sinusoidal or small venous fibrous occlusive disease characterized by small hepatic vessel damage, especially sinusoidal endothelial cell injury.Exposure to certain exogenous toxins is the main cause of the disease.Based on etiology, HSOS is mainly classified into pyrrolidine alkaloid-related HSOS, hematopoietic stem cell transplantation-related HSOS, and HSOS of unknown etiology.This article summarizes the types of HSOS and reviews the research advances in clinical manifestations, pathogenesis, diagnosis, and treatment of HSOS.
- hepatic veno-occlusive disease /
- alkaloids /
- hematopoietic stem cell transplantation /
- review

HTML全文

参考文献(54)

[1]HILL KR, RHODES K, STAFFORD JL, et al.Serous hepatosis:A pathogenesis of hepatic fibrosis in jamaican children[J].Br Med J, 1953, 1 (4802) :117-122.

[2]BRAS G, JELLIFFE DB, STUART KL.Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica[J].AMA Arch Pathol, 1954, 57 (4) :285-300.

[3]DELEVE LD, MCCUSKEY RS, WANG X, et al.Characterization of a reproducible rat model of hepatic veno-occlusive disease[J].Hepatology, 1999, 29 (6) :1779-1791.

[4]DELEVE LD, SHULMAN HM, MCDONALD GB.Toxic injury to hepatic sinusoids:Sinusoidal obstruction syndrome (veno-occlusive disease) [J].Semin Liver Dis, 2002, 22 (1) :27-42.

[5]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1637.

[6] HOU JG, XIA YT, YU CS, et al.Hepatic veno-occlusive disease:A report of 2 cases[J].Chin J Intern Med, 1980, 19:187-191. (in Chinese) 侯景贵, 夏玉亭, 余昌时, 等.肝小静脉闭塞病-附2例报告[J].中华内科杂志, 1980, 19:187-191.

[7]GUO Y, ZHANG SR, WEN LZ, et al.Clinical features of sinusoidal obstruction syndrome induced by pyrrolidine alkaloids in China[J].J Clin Hepatol, 2018, 34 (6) :1277-1281. (in Chinese) 郭严, 张世荣, 文良志, 等.我国吡咯烷生物碱致肝窦阻塞综合征的临床特征分析[J].临床肝胆病杂志, 2018, 34 (6) :1277-1281.

[8]PRAKASH AS, PEREIRA TN, REILLY PE, et al.Pyrrolizidine alkaloids in human diet[J].Mutat Res, 1999, 43 (1-2) :53-67.

[9]YANG M, RUAN J, GAO H, et al.First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J].Arch Toxicol, 2017, 91 (12) :3913-3925.

[10] CHEN Z, HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations[J].Neth J Med, 2010, 68 (6) :252-260.

[11]WANG X, KANEL GC, DELEVE LD.Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat[J].Hepatology, 2000, 31 (2) :428-434.

[12]DELEVE LD, WANG X, TSAI J, et al.Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition[J].Gastroenterology, 2003, 125 (3) :882-890.

[13]YU XZ, JI T, BAI XL, et al.Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum[J].J Zhejiang Univ Sci B, 2013, 14 (1) :68-75.

[14]OKUNO M, HATANO E, NAKAMURA K, et al.Regorafenib suppresses sinusoidal obstruction syndrome in rats?[J].Surg Res, 2015, 193 (2) :693-703.

[15]CHEN Z, HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations[J].Neth J Med, 2010, 68 (6) :252-260.

[16]WADLEIGH M, HO V, MOMTAZ P, et al.Hepatic veno-occlusive disease:Pathogenesis, diagnosis and treatment[J].Curr Opin Hematol, 2003, 10 (6) :451-462.

[17]ZHANG J, SHENG Y, LIANG S, et al.Quercetin and baicalein suppress monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats[J].Eur J Pharmacol, 2017, 795:160-168.

[18]HARB R, XIE G, LUTZKO C, et al.Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury[J].Gastroenterology, 2009, 137 (2) :704-712.

[19]VALLA DC, CAZALSHATEM D.Sinusoidal obstruction syndrome[J].Clin Res Hepatol Gastroenterol, 2016, 14 (4) :651-658.

[20]SHULMAN HM, MCDONALD GB, MATTHEWS D, et al.An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation[J].Gastroenterology, 1980, 79 (6) :1178-1191.

[21]CARRERAS E, BERTZ H, ARCESE W, et al.Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation:A prospective cohort study of the European Group for Blood and Marrow Transplantation.European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party[J].Blood, 1998, 92 (10) :3599-3604.

[22]MOHTY M, MALARD F, ABECASSIS M, et al.Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients:A new classification from the European Society for Blood and Marrow Transplantation[J].Bone Marrow Transplant, 2016, 51 (7) :906-912.

[23]DELEVE LD, VALLA DC, GARCIA-TSAO G.Vascular disorders of the liver[J].Hepatology, 2009, 49 (5) :1729-1764.

[24]FAN ZP, LIU ZL, LIN W, et al.Comparison of stem cell transplantation with pyrrolidene-associated hepatic venous occlusion syndrome[J].J Mod Med Health, 2018, 34 (13) :1949-1952, 1955. (in Chinese) 范作鹏, 刘贞利, 林伟, 等.干细胞移植与吡咯生物碱相关肝窦阻塞综合征的比较[J].现代医药卫生, 2018, 34 (13) :1949-1952, 1955.

[25]DEVARBHAVI H, SINGH R, PATIL M, et al.Outcome and determinants of mortality in 269 patients with combination antituberculosis drug-induced liver injury[J].J Gastroenterol Hepatol, 2013, 28 (1) :161-167.

[26]KIM J, JUNG Y.Radiation-induced liver disease:Current understanding and future perspectives[J].Exp Mol Med, 2017, 49 (7) :e359.

[27]DIGNAN FL, WYNN RF, HADZIC N, et al.BCSH/BSBMTguideline:Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J].Br J Haematol, 2013, 163 (4) :444-457.

[28]HAUSSMANN U, FISCHER J, EBER S, et al.Hepatic venoocclusive disease in pediatric stem cell transplantation:Impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy[J].Haematologica, 2006, 91 (6) :795-800.

[29]NAKAMURA D, YOSHIMITSU M, KAWADA H, et al.Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post al ogeneic hematopoietic SCT[J].Bone Marrow Transplant, 2012, 47 (3) :463-464.

[30]YOON JH, MIN WS, KIM HJ, et al.Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT:Is it still reasonable to use t-PA?[J].Bone Marrow Transplant, 2013, 48 (12) :1562-1568.

[31]WEISCHENDORFF S, KIELSEN K, SENGELOV H, et al.Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation[J].Bone Marrow Transplant, 2017, 52 (6) :863.

[32]van CUTSEM E, CERVANTES A, NORDLINGER B, et al.Metastatic colorectal cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2014, 25 (Suppl 3) :iii1-iii9.

[33]VIGANO L, CAPUSSOTTI L, DE RG, et al.Liver resection for colorectal metastases after chemotherapy:Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival[J].Ann Surg, 2013, 258 (5) :731-740.

[34]NGUYENKHAC E, LOBRY C, CHATELAIN A, et al.A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics[J].Int J Hepatol, 2013, 2013:314868.

[35]RUBBIABRANDT L, AUDARD V, SARTORETTI P, et al.Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J].Ann Oncol, 2004, 15 (3) :460-466.

[36]RUBBIA-BRANDT L, LAUWERS GY, WANG H, et al.Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis[J].Histopathology, 2010, 56 (4) :430-439.

[37]HUBERT C, SEMPOUX C, HUMBLET Y, et al.Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases:Factors predictive of severe SOS lesions and protective effect of bevacizumab[J].HPB, 2013, 15 (11) :858-864.

[38]ROBINSON SM, WILSON CH, BURT AD, et al.Chemotherapy-associated liver injury in patients with colorectal liver metastases:A systematic review and meta-analysis[J].Ann Surg Oncol, 2012, 19 (13) :4287-4299.

[39]van der POOL AE, MARSMAN HA, VERHEIJ J, et al.Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases[J].J Surg Oncol, 2012, 106 (7) :892-897.

[40]JAFARI A, MATTHAEI H, WEHNER S, et al.Bevacizumab exacerbates sinusoidal obstruction syndrome (SOS) in the animal model and increases MMP 9 production[J].Oncotarget, 2018, 9 (31) :21797-21810.

[41]ROBINSOM SM, MANN J, VASILAKI A, et al.Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model[J].J Hepatol, 2013, 59 (2) :318-326.

[42]RUBBIABRANDT L, TAUZIN S, BREZAULT C, et al.Gene expression profiling provides insights into pathways of oxaliplatinrelated sinusoidal obstruction syndrome in humans[J].Mol Cancer Ther, 2011, 10 (4) :687-696.

[43]AGOSTINI J, BENOIST S, SEMAN M, et al.Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation[J].J Hepatol, 2012, 56 (4) :869-876.

[44]ROBINSON SM, MANN DA, MANAS DM, et al.The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome[J].British J Cancer, 2013, 109 (9) :2396-2403.

[45]HIRATA M, TAJIMA H, MIYASHITA T, et al.Extravasated platelet aggregation in the livers of rats with druginduced hepatic sinusoidal obstruction syndrome[J].Mol Med Rep, 2017, 15 (5) :3147-3152.

[46]LEHMANN K, RICKENBACHER A, WEBER A, et al.Chemotherapy before liver resection of colorectal metastases:Friend or foe?[J].Ann Surg, 2012, 255:237-247.

[47]SOUBRANE O, BROUQUET A, ZALINSKI S, et al.Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases:correlation with post-hepatectomy outcome[J].Ann Surg, 2010, 251 (3) :454-460.

[48]VREULS CP, MA VDB, WINSTANLEY A, et al.Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases[J].Histopathology, 2012, 61 (6) :314-318.

[49]VREULS CP, OLDE DAMINK SW, KOEK GH, et al.Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer[J].Br J Cancer, 2013, 108 (3) :676-680.

[50]HAN NY, PARK BJ, SUNG DJ, et al.Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy:Gadoxetic acid-enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation[J].Radiology, 2014, 271 (2) :416-425.

[51]TAKAMURA H, NAKANUMA S, HAYASHI H, et al.Severe veno-occlusive disease/sinusoidal obstruction syndrome after deceased-donor and living-donor liver transplantation[J].Transplant Proc, 2014, 46 (10) :3523-3535.

[52]WANG T, ONG P, ROSCIOLI T, et al.Hepatic veno-occlusive disease with immunodeficiency (VODI) :First reported case in the U.S.and identification of a unique mutation in Sp110[J].Clin Immunol, 2012, 145 (2) :102-107.

[53]MARQUARDSEN FA, BALDIN F, WUNDERER F, et al.Detection of Sp110 by flow cytometry and application to screening patients for veno-occlusive disease with immunodeficiency[J].Clin Immunol, 2017, 37 (7) :707-714.

[54]TALLMAN MS, MCDONALD GB, DELEVE LD, et al.Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin) :A prospective observational study of 482 patients in routine clinical practice[J].Int J Hematol, 2013, 97 (4) :456-464.

施引文献

资源附件(0)

访问统计